evidence table
Ashwagandha and Stress Evidence Table
Structured evidence table for Ashwagandha and Stress, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ashwagandha and Stress | There is a paucity of evidence assessing the efficacy and safety of low-dose formulations of Ashwagandha in stress management. | 2 | Thanawala Shefali (2026) | Efficacy and safety of Ashwagandha root extract sustained-release (AshwaSR) capsules in healthy adult, stressed subjects: A randomized, double-blind, placebo-controlled, parallel-group, 3-arm clinical trial |
| Ashwagandha and Stress | We evaluated the efficacy and safety of AshwaSR capsules at doses of 150 and 300 mg in reducing stress and associated symptoms in healthy adults experiencing stress, over a period of 60 days of administration. | 2 | Thanawala Shefali (2026) | Efficacy and safety of Ashwagandha root extract sustained-release (AshwaSR) capsules in healthy adult, stressed subjects: A randomized, double-blind, placebo-controlled, parallel-group, 3-arm clinical trial |
| Ashwagandha and Stress | Items were designed to determine how unpredictable, uncontrollable, and overloaded subjects found their lives, with response scores ranging between 0 and 40 (scores 0–13, low; 14–26, moderate; 27–40, high perceived stress). | 2 | Thanawala Shefali (2026) | Efficacy and safety of Ashwagandha root extract sustained-release (AshwaSR) capsules in healthy adult, stressed subjects: A randomized, double-blind, placebo-controlled, parallel-group, 3-arm clinical trial |
| Ashwagandha and Stress | 1 2 [,] 3 4 [,] 5 [] Stress is a normal response to difficult situations in an individual’s life; however, prolonged and excessive mental or physical stress can be detrimental. | 2 | Thanawala Shefali (2026) | Efficacy and safety of Ashwagandha root extract sustained-release (AshwaSR) capsules in healthy adult, stressed subjects: A randomized, double-blind, placebo-controlled, parallel-group, 3-arm clinical trial |
| Ashwagandha and Stress | These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ashwagandha and Stress | Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ashwagandha and Stress | Rhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ashwagandha and Stress | 1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally (). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
Source documents
- Efficacy and safety of Ashwagandha root extract sustained-release (AshwaSR) capsules in healthy adult, stressed subjects: A randomized, double-blind, placebo-controlled, parallel-group, 3-arm clinical trial
- Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders